Enhancing the adjuvant treatment of hormone receptor positive breast cancer

Breast Journal

Volumn 15, Issue 2, 2009, Pages 194-198

  Barry, Mitchel ^a   Kell, Malcolm R ^a  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Anastrozole; Aromatase inhibitors; Letrozole; Optimum adjuvant treatment

Indexed keywords

ANASTROZOLE; AROMATASE; ESTROGEN RECEPTOR; LETROZOLE; TAMOXIFEN; VOROZOLE;

ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE FREE SURVIVAL; DRUG EFFICACY; FRACTURE; HOT FLUSH; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; VAGINA BLEEDING;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NITRILES; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REGISTRIES; SURVIVAL ANALYSIS; SURVIVORS; TRIAZOLES;

EID: 62149092123     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2009.00696.x     Document Type: Article

References (16)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005 365 : 1687 717.
2. ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005 365 : 60 2.
3. Geisler J, King N, Dowsett M, et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 1996 74 : 1286 91.
4. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000 18 : 3758 67.
5. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001 19 : 2596 606.
6. Buzdar AU, Jonat W, Howell A, et al. Anasrtrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol 2001 19 : 3357 66.
7. Coates AS, Keshariah A, Thurliman B, et al. Breast International Group 1-98 Collaborative Group: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of Study BIG 1-98. J Clin Oncol 2007 25 : 486 92.
8. Coombes RC, Hall E, Gibson LJ, et al. Intergroup exemestane study: a randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Eng J Med 2004 350 : 1081 92.
9. Jakesz R, Jonat W, Gnant M, et al. ABCSG and the GABG: Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trail. Lancet 2005 366 : 455 62.
10. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early stage breast cancer. N Eng J Med 2003 349 : 1793 802.
11. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005 23 : 619 29.
12. McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ. The Scottish Cancer Trials Breast Group. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomized trial. Br Med J 1995 311 : 977 80.
13. Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007 25 : 829 36.
14. Braithwaite RS, Chlebowski RT, Lau J, et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 2003 18 : 937 47.
15. Rose C, Vtoraya O, Pluzanska A, et al. Letrozole (Femara) versus anastrozole (Arimidex): second-line treatment in postmenopausal women with advanced breast cancer. Proc Am Soc Clin Oncol 2002 21 : 34.
16. Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L. Hormonal therapies for early breast cancer: systematic review and economic evaluation. Health Technol Assess 2007 11 : 1 134.